Becker's Healthcare March 25, 2024
Madeline Ashley

Medicare total spending hit $5.7 billion in 2022 for GLP-1 drugs such as Ozempic, Wegovy and Mounjaro, up from $57 million in 2018, according to a March 22 KFF analysis.

GLP-1 drugs were originally developed to treat Type 2 diabetes but have since gained popularity as medications used to tackle obesity.

While Medicare is not allowed under existing law to cover the drugs for weight loss, Medicare Part D plans can cover them for other medically accepted indications, such as reducing cardiovascular risk, according to a recent...

Today's Sponsors

LEK
ZeOmega

Today's Sponsor

LEK

 
Topics: Biotechnology, CMS, Govt Agencies, Insurance, Medicare, Patient / Consumer, Pharma / Biotech, Provider, Survey / Study, Trends
109 hospitals receiving new Medicare-backed residency slots
Senators urge Congress to avert Medicare physician pay cut
Podcast: Medicare Shared Savings Program Mints $2B Win for Value-Based Care w/ Frank McStay
Medicare Part D in 2025: A First Look at Prescription Drug Plan Availability, Premiums, and Cost Sharing
Dr. Oz, RFK Jr. on Medicare, Medicaid: 10 notes

Share This Article